NovoCure
NVCR
176 hedge funds and large institutions have $2.9B invested in NovoCure in 2018 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 64 increasing their positions, 59 reducing their positions, and 15 closing their positions.
294% more call options, than puts
Call options by funds: $63.9M | Put options by funds: $16.2M
107% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 15
75% more capital invested
Capital invested by funds: $1.66B → $2.9B (+$1.24B)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
9% more funds holding
Funds holding: 161 → 176 (+15)
1.48% more ownership
Funds ownership: 58.33% → 59.81% (+1.5%)
8% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 59
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$119M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$54.7M |
| 3 |
DCP
Darsana Capital Partners
New York
|
+$32.8M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$20.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$24.4M |
| 2 |
HCM
Highline Capital Management
New York
|
-$24.3M |
| 3 |
PC
PointState Capital
New York
|
-$22.5M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$22.3M |
| 5 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$18.5M |
NVCR Hedge Fund Activity: Q3 2018 in Review
176 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2018, worth a combined $2.9B — up 75% from $1.66B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new NVCR positions and 15 closed out — a net gain of 16 holders — while 64 added to existing stakes and 59 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $119M. The largest seller was Citadel Advisors, cutting an estimated $24.4M.
- 176 institutional investors held NovoCure (NVCR) as of Q3 2018, up from 161 in Q2 2018.
- Funds reported $2.9B of NovoCure stock for Q3 2018, up 75% quarter-over-quarter.
- 31 funds opened new NovoCure positions in Q3 2018 and 15 closed out, a net change of +16 holders.
- The largest NovoCure buyer in Q3 2018 was Fidelity Investments, an estimated $119M added.
- The largest NovoCure seller in Q3 2018 was Citadel Advisors, an estimated $24.4M sold.
Based on aggregated 13F filings for Q3 2018.